Novel Technology Has Made It Possible To Diagnose A New Clinical Phenotype Of Rejection Called Early Antibody Mediated Rejection, With Significant Therapeutic Implications For Renal Allograft Survival
Discover how MMDx Kidney can diagnose antibody-mediated rejection (AMBR) when histopathology is discordant with the clinical scenario. While there is still no FDA-approved treatment for ABMR. It is suggested that identifying early ABMR could lead to intervention and the prevention of graft loss due to chronic active ABMR.